Want to see CH:MEDX full AI Analyst Report?
MEDX Stock Chart & Stats
CHF8.19
-CHF0.06(-0.73%)
At close: 4:00 PM EDT
CHF8.19
-CHF0.06(-0.73%)
Day’s Range― - ―
52-Week RangeCHF7.61 - CHF12.36
Previous CloseN/A
Volume153.47K
Average Volume (3M)115.75K
Market Cap
CHF380.85M
Enterprise ValueCHF610.90
Total Cash (Recent Filing)CHF111.30M
Total Debt (Recent Filing)CHF319.40M
Price to Earnings (P/E)3712.0
Beta0.98
Next Earnings
Feb 23, 2027EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend Yield1.08%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding41,262,370
10 Day Avg. Volume183,978
30 Day Avg. Volume115,752
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.08
Price to Sales (P/S)1.02
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.56
Revenue Forecast (FY)CHF447.29M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenuemedmix's core sales include consumable mixers, nozzles and tips that are used repeatedly in customers' production and clinical workflows. That recurring consumables demand supports predictable revenue streams, reduces reliance on one-time equipment sales, and underpins durable topline resilience.
Engineering Capability And OEM Supply RelationshipsThe business offers application development, customization and design-for-manufacture, and supplies customer-specific OEM components. These technical capabilities create switching costs and long-term supply contracts, anchoring volumes and enabling margin capture across customer lifecycles.
Positive Operating And Free Cash FlowDespite volatility, medmix generated positive operating and free cash flow in 2025, providing internal funding for capex, R&D and working capital. Positive cash generation is a durable strength that supports reinvestment and debt servicing even if earnings remain thin.
Bears Say
Revenue Decline / Soft DemandTop-line has stalled and declined recently, signalling softer end-market demand or lost volumes. Sustained revenue weakness impairs scale economics, limits operating leverage and makes durable margin expansion and consistent earnings growth more difficult over the medium term.
Thin And Fragile Net MarginsNet margin near 1% leaves little buffer against cost inflation, input-price swings or volume declines. Thin profitability makes earnings volatile, constrains free cash flow upside, and reduces capacity to fund strategic initiatives without relying on improved revenue or cost restructuring.
Rising Leverage Reduces Financial FlexibilityLeverage approaching parity with equity increases interest and covenant risk, limiting flexibility for acquisitions, R&D or capital spending. Higher debt relative to prior years reduces resilience to downturns and raises financing cost sensitivity over the medium term.
medmix AG News
MEDX FAQ
What was medmix AG’s price range in the past 12 months?
medmix AG lowest stock price was CHF7.61 and its highest was CHF12.36 in the past 12 months.
What is medmix AG’s market cap?
medmix AG’s market cap is CHF380.85M.
When is medmix AG’s upcoming earnings report date?
medmix AG’s upcoming earnings report date is Feb 23, 2027 which is in 193 days.
How were medmix AG’s earnings last quarter?
medmix AG released its earnings results on Jul 23, 2026. The company reported CHF0.32 earnings per share for the quarter, missing the consensus estimate of CHF0.35 by -CHF0.03.
Is medmix AG overvalued?
According to Wall Street analysts medmix AG’s price is currently Overvalued.
Does medmix AG pay dividends?
medmix AG pays a Annually dividend of CHF0.1 which represents an annual dividend yield of 1.08%. See more information on medmix AG dividends here
What is medmix AG’s EPS estimate?
medmix AG’s EPS estimate is 0.42.
How many shares outstanding does medmix AG have?
medmix AG has 41,262,370 shares outstanding.
What happened to medmix AG’s price movement after its last earnings report?
medmix AG reported an EPS of CHF0.32 in its last earnings report, missing expectations of CHF0.35. Following the earnings report the stock price went down -4.01%.
Which hedge fund is a major shareholder of medmix AG?
Currently, no hedge funds are holding shares in CH:MEDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
medmix AG
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixing, application, and injection of liquids across various viscosities, serving diverse healthcare, consumer, and industrial markets worldwide. The company operates through five key divisions: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers essential tools such as mixing tips, dispensers, needles, and accessories, alongside support services for applications including prosthetics, restorative procedures, anesthesiology, and cosmetic dentistry. In its Drug Delivery segment, Medmix develops critical devices for administering medications like fertility drugs, growth hormones, and treatments for specific diabetes conditions, osteoporosis, and rare diseases. The Surgery segment provides specialized mixing and delivery systems utilized for injecting bone cement and applying hemostatic sealants to manage both internal and external wounds during surgical interventions. For industrial clients, the Industry division produces robust dispensers, cartridges, and mixers for two-component adhesives and sealants, indispensable in sectors such as construction, transportation, electronics, infrastructure, and broader manufacturing. Lastly, the Beauty segment supplies micro brushes, mascara applicators, lip gloss, and concealers. Medmix AG markets its comprehensive product range under well-recognized brands, including Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka.
Technical Analysis
Rieter Holding AG
―
Komax Holding AG
―
―
Mikron Holding AG
―
StarragTornos Group AG
―







